




2013 1H Financial Results & Business Update

Stock Code: 00853(HK)



June 2013



-  2013 1H Financial Results
-  Business Update

Key Financial Summary


- Revenue: 422m, Y/Y 13%
- Net profit: 92m, Y/Y 59%

Financial Performance

Revenue & Gross Margin

(RMB million)


5Y CAGR: 18%



Net Profit & Net Margin


(RMB million)

5Y CAGR: 19%




Business Diversification - Revenue Mix for Reference

Revenue by Products (2013 1H)




Revenue by Products (2012 1H)



Operating Expenses

Sales and Marketing Cost


(RMB million)



Y/Y: 0.6%

Administrative Expense


(RMB million)



Y/Y:

Research and Development Cost

(RMB million)



Y/Y:

Vascular Business

Electrophysiology Business

Orthopedics Business

Diabetes and Endocrinal Devices


Surgical Management Dongguan Kewei

Long-Term R&D Pipeline

1-1 Vascular Business


DES-Firehawk R&D Status

Firebird 2



Commercially launched in **January 2009**
Constructed of **cobalt-chromium** coated with sirolimus
0.034 inch thick

Firehawk




Third generation DES
Cobalt-chromium **target-eluting** stent coated with sirolimus
Biodegradable drug coating that attaches only to the area of stent that contacts the blood vessel

Update of Firehawk

The results of **All Trials** was published on **CIT 2013** (Mar. 2013)
Waiting for SFDA approval and CE approval

DES Revenue (2008-2013 1H)


RMB: million



1-2 Vascular Business


Endovascular Stent Graft

TAA/AAA Market Leadership (2012)




Products Profile

Castor




Branched Aortic Stent-Graft and Delivery System
 Clinical Trial to be kicked off in 2012

Hercules B / Hercules T



Solid Growth of Apollo in Revenue

Products Already Received SFDA Approval



Tubridge

Vascular Reconstruction Device
First-in-man Finished in 2011
Clinical

2 Electrophysiology Business

Solid Growth of Electrophysiology in Revenue


RMB: million




R&D Pipeline

Columbus

3D Mapping System
Clinical Trial in 2012




Products on the Market



Voyager

Irrigated RF Ablation Catheter
Clinical Trial in 2012




3 Orthopedics Business

Milestones

-  **2009**
 Established Shanghai MicroPort Orthopedics
-  **2010**
 Obtained CE Certificates for over 5 products since 2010
-  **2011**
 Acquired Suzhou BEST Orthopedics Corporation
-  **2012**
 Revenues generated from domestic & international sales

Sales Split by Application





Key Factors



Employee: 180 in total
 Facilities: increase an area of 11,000m²
 Certificates: over 20 domestic registration certificates, and over 5 CE certificates

Products Profile Pipeline




Solid Growth of Diabetes Business in Revenue

Products Profile

Micro-Infusion GnRH Pump (Artificial Pituitary Pump)

Innovative Solution for Hypogonadotropic Hypogonadism (HH)

Contribute a lot to the revenue


R&D Pipeline

La Fenice V



New generation Insulin Pum
Clinical Trial Finished



La Fenice Pen

Motor Drive Insulin Pen
Clinical Trial to be kicked off in 2013



5 Surgical Devices Business

Key Factors




Located on Dongguan, Guangdong province
 28 patents in China
 Around 160 employees, over 20 engineers and 10 sales
 Products currently used in more than 150 hospitals

Products

- Oxygenator
- Blood Storage Filter
- Disposable Cardiotomy Irrigator
- Occluder
- Occluder




Oxygenators Market Leadership



Source: Guohai Securities Research Center , Feb. 2011


Revenue of 2013 1H



Pacemaker & Pacing Lead

IPG (Implantable Pulse Generator)

Under R&D stage



Pacing Leads active & passive

Under R&D stage



Others

Transcatheter Aortic Valve Implantation system

Under R&D stage



Renal Denervation Device

Under R&D stage

Appendix I - Consolidated Income Statement

(RMB '000)	2013 1H Actual	2012 1H Actual
Revenue	421,922	484,916
Cost of sales	(79,506)	(71,833)
Gross profit	342,416	413,083
Other revenue & net income	18,923	25,811
Research and development costs	(84,260)	(62,824)
Sales and marketing costs	(64,489)	(64,886)
Administrative expenses	(51,983)	(46,637)
Other operating costs	(43,764)	(313)
Operating Profit	116,843	264,234
Finance costs	(1,543)	(327)
Profit before taxation	115,300	263,907
Income tax	(23,190)	(41,236)
Net profit	92,110	222,671

Appendix II - Consolidated Balance Sheet

RMB'000	30 Jun 2013	31 Dec 2012
Cash and cash equivalents	662,227	413,149
Deposits with banks	451,528	666,275
Trade & Other receivables	390,343	433,890
Inventories	109,522	92,654
Total current assets	1,613,620	1,605,968
Fixed Assets & CIP & Prepay for FA	824,765	720,497
Intangible assets	167,568	149,974
Goodwill	154,955	175,492
Deferred tax assets	15,477	15,949
Total non-current assets	1,162,765	1,061,912
Total assets	2,776,385	2,667,880
Interest-bearing borrowings	(498)	(20,491)
Trade & Other payables	(267,392)	(174,812)
Income tax payable	(14,908)	(9,011)
Deferred income	(215)	(257)
Total current liabilities	(283,013)	(204,571)
Interest-bearing borrowings	(2,745)	(2,703)
Deferred income	(104,072)	(71,125)
Deferred tax liabilities	(27,355)	(28,923)
Other non-current liabilities	(41,691)	(40,679)
Total liabilities	(458,876)	(348,001)
Share capital	(108)	(108)
Capital reserve	(2,317,401)	(2,319,771)
Total stockholders' equity	(2,317,509)	(2,319,879)
Total liabilities and equity	(2,776,385)	(2,667,880)
Net Current Assets	1,330,607	1,401,397
Net Assets	2,317,509	2,319,879

Appendix III

Condensed Consolidated Cash Flow Statement - Adjusted

(RMB '000)	2013 1H Actual	2012 1H Actual
Cash generate from operations	198,573	196,529
Income tax paid	(18,388)	(29,131)
Net cash generated from operating activities	180,185	167,398
Net cash (used in)/from investing activities	(98,851)	(164,935)
Net cash used in financing activities	(50,036)	(25,963)
Net decrease in cash and cash equivalent	31,298	(23,499)
Cash and cash equivalents at 1 January	1,079,424	1,414,488
Effect of foreign exchange rate changes	3,033	(971)
Cash and cash equivalents at 30 June	1,113,755	1,390,017

* Adjusted 215 million net placement of time deposits with bank over 3 month(2012 1H: net uplift 781 million) in to cash and cash equivalents.

This document is for information purposes only and does not constitute or form part of any offer or invitation to sell or the solicitation of an offer or invitation to purchase or subscribe for any securities of MicroPort Scientific Corporation, and no part of it shall form the basis of, or be relied upon in connection with, any agreement, arrangement, contract, commitment or investment decision in relation thereto whatsoever.

FORWARD-LOOKING STATEMENTS

Some information contained on this website contains forward-looking statements. These forward-looking statements include, without limitation, those regarding our future financial position, our strategy, plans, objectives, goals and targets, future developments in the markets where we participate or are seeking to participate, and any statements preceded by, followed by or that include the words "believe", "intend", "expect", "anticipate", "project", "estimate", "predict", "is confident", "has confidence" and similar expressions are also intended to identify forward-looking statements. Such statements are based upon the current beliefs and expectations of management and are subject to significant risks and uncertainties. MicroPort Scientific Corporation undertakes no obligation to update any of the statements. These forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and other factors that could cause actual future results to differ materially from current expectations include, but are not limited to, general industry and economic conditions, PRC governmental policies and regulations relating to the medical device manufacturing industry, competition in the medical device manufacturing industry, our ability to develop



Thank You